Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 19, 2020 - Issue 10
Submit an article Journal homepage
464
Views
3
CrossRef citations to date
0
Altmetric
Original research

Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study

Franco Citterioa Department of Surgery, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ItalyCorrespondence[email protected]
View further author information
,
Mitchell Henryb Department of Surgery, The Comprehensive Transplant Center, The Ohio State University, Wexner Medical Center, Columbus, OH, USAView further author information
,
Dean Y Kimc Department of Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, USAView further author information
,
Myoung Soo Kimd Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of KoreaView further author information
,
Duck-Jong Hane Department of Surgery, Asan Medical Center, Seoul, Republic of South KoreaView further author information
,
Takashi Kenmochif Department of Transplant Surgery, Fujita Health University, Toyoake, JapanView further author information
,
Eytan Morg Department of Surgery, Transplant Center at Sheba Medical Center, Ramat-Gan, IsraelView further author information
,
Giuseppe Tisoneh Department of Surgery HPB and Transplant Unit, University of Tor Vergata, Rome, ItalyView further author information
,
Peter Bernhardti Department of Research and Development, Novartis Pharma AG, Basel, SwitzerlandView further author information
,
Maria Pilar Hernandez Gutierrezi Department of Research and Development, Novartis Pharma AG, Basel, SwitzerlandView further author information
&
Yoshihiko Wataraij Department of Transplant Surgery and Nephrology, Nagoya Daini Red Cross Hospital, Nagoya-City, JapanView further author information
 show all
Pages 1339-1348 | Received 10 Jun 2020, Accepted 02 Jul 2020, Published online: 20 Jul 2020

References

  • Ventura-Aguiar P, Campistol JM, Diekmann F. Safety of mTOR inhibitors in adult solid organ transplantation. Expert Opin Drug Saf. 2016;15:303–319.
  • Nashan B, Citterio F. Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature. Transplantation. 2012;94:547–561.
  • Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant. 2010;10:1401–1413.
  • Qazi Y, Shaffer D, Kaplan B, et al. Efficacy and safety of everolimus plus low-dose tacrolimus versus mycophenolate mofetil plus standard-dose tacrolimus in de novo renal transplant recipients: 12-month data. Am J Transplant. 2017;17:1358–1369.
  • Shihab FS, Cibrik D, Chan L, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clin Transplant. 2013;27:217–226.
  • Shihab F, Qazi Y, Mulgaonkar S, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus. Am J Transplant. 2017;17:2363–2371.
  • Cooper M, Wiseman AC, Zibari G, et al. Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials. Clin Transplant. 2013;27:E625–E635.
  • Ueno P, Felipe C, Ferreira A, et al. Wound healing complications in kidney transplant recipients receiving everolimus. Transplantation. 2017;101:844–850.
  • Pascual J, Srinivas TR, Chadban S, et al. TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation. Open Access J Clin Trials. 2014;6:45–54.
  • Pascual J, Berger SP, Witzke O, et al. Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol. 2018;29:1979–1991.
  • Tedesco-Silva H, Pascual J, Viklicky O, et al. Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study. Transplantation. 2019;103:1953–1963.
  • Berger SP, Sommerer C, Witzke O, et al. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from TRANSFORM study. Am J Transplant. 2019;19:3018–3034.
  • Sommerer C, Suwelack B, Dragun D, et al. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. Kidney Int. 2019;96:231–244.
  • Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation. 2009;88:69–76.
  • Dantal J, Berthoux F, Moal MC, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transplant Int. 2010;23:1084–1093. Erratum in: Transpl Int. 2012;25:138.
  • Manzia TM, Carmellini M, Todeschini P, et al. A 3-month, multicenter, randomized, open-label study to evaluate the impact on wound healing of the early (vs. delayed) introduction of everolimus in de novo kidney transplant recipients, with a follow-up evaluation at 12 month after transplant (NEVERWOUND study). Transplantation. 2020;104:374–386.
  • Cibrik D, Silva HT Jr, Vathsala A, et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation. 2013;95:933–942.
  • Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation. 2004;77:1555–1561.
  • Knight RJ, Villa M, Laskey R, et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transplant. 2007;21:460–465.
  • Grim SA, Slover CM, Sankary H, et al. Risk factors for wound healing complications in sirolimus-treated renal transplant recipients. Transplant Proc. 2006;38:3520–3523.
  • Zuckermann A, Barten MJ. Surgical wound complications after heart transplantation. Transpl Int. 2011;24:627–636.
  • Koch M, Kantas A, Ramcke K, et al. Surgical complications after kidney transplantation: different impacts of immunosuppression, graft function, patient variables, and surgical performance. Clin Transplant. 2015;29:252–260.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.